Mital Patel - RadNet Executive Vice President - Finance
| RDNT Stock | USD 81.76 0.73 0.88% |
President
Mr. Mital Patel is the Executive Vice President of Financial Planning and Analysis. Mr. Patel has over a decade of senior healthcare management experience, and prior to joining us, he was a Director of Physician Liaison for Truxtun Radiology, where he helped grow practice revenue, managed operation initiatives and Quality Compliance measures and assisted in managing Truxtuns acquisition by RadNet. Mr. Patel has also been very active in the community, having held board seats in several nonprofit organizations since 2016.
| Age | 38 |
| Tenure | 8 years |
| Address | 1510 Cotner Avenue, Los Angeles, CA, United States, 90025 |
| Phone | 310 478 7808 |
| Web | https://www.radnet.com |
RadNet Management Efficiency
The company has return on total asset (ROA) of 0.0239 % which means that it generated a profit of $0.0239 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.032 %, meaning that it created $0.032 on every $100 dollars invested by stockholders. RadNet's management efficiency ratios could be used to measure how well RadNet manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to 0 in 2024. Return On Capital Employed is likely to gain to 0.05 in 2024. At this time, RadNet's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 2.8 B in 2024, whereas Non Current Liabilities Other is likely to drop slightly above 6.4 M in 2024.Similar Executives
| Found 12 records | PRESIDENT Age | ||
| Michael Rutz | Sotera Health Co | 53 | |
| Jonathan Sheldon | Qiagen NV | 52 | |
| Mark Verratti | Myriad Genetics | 56 | |
| Joseph Shrawder | Sotera Health Co | N/A | |
| Luciano Bonanni | Fonar | 69 | |
| Thomas Schweins | Qiagen NV | N/A | |
| Steven PharmD | Aclaris Therapeutics | N/A | |
| MD DO | Aclaris Therapeutics | 54 | |
| Hugh Davis | Aclaris Therapeutics | 65 | |
| Riaz MBA | Sotera Health Co | 54 | |
| Neal DO | Aclaris Therapeutics | 54 | |
| Robert Donofrio | Neogen | 49 | |
Management Performance
| Return On Equity | 0.032 | ||||
| Return On Asset | 0.0239 |
RadNet Inc Leadership Team
Elected by the shareholders, the RadNet's board of directors comprises two types of representatives: RadNet inside directors who are chosen from within the company, and outside directors, selected externally and held independent of RadNet. The board's role is to monitor RadNet's management team and ensure that shareholders' interests are well served. RadNet's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, RadNet's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mital Patel, Executive Vice President - Finance | ||
| Christine Gordon, Senior California | ||
| Ranjan Jayanathan, Chief VP | ||
| Norman Hames, COO of Western Operations, Executive VP, Secretary and Director | ||
| Michael Murdock, Executive Acquisitions | ||
| Howard MD, President Chairman | ||
| Stephen Forthuber, COO of Eastern Operations and Executive VP | ||
| Ruth VilligerWilson, HR Director | ||
| Gregory MD, Chief VP | ||
| BSRT MPH, VP Affairs | ||
| David Katz, Chief VP | ||
| Mark Stolper, CFO and Executive VP | ||
| Derek Bomar, Senior Management |
RadNet Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is RadNet a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.032 | ||||
| Return On Asset | 0.0239 | ||||
| Profit Margin | (0) % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 7.04 B | ||||
| Shares Outstanding | 74.03 M | ||||
| Shares Owned By Insiders | 10.62 % | ||||
| Shares Owned By Institutions | 87.15 % | ||||
| Number Of Shares Shorted | 3.48 M | ||||
| Price To Earning | 55.56 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for RadNet Stock Analysis
When running RadNet's price analysis, check to measure RadNet's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RadNet is operating at the current time. Most of RadNet's value examination focuses on studying past and present price action to predict the probability of RadNet's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RadNet's price. Additionally, you may evaluate how the addition of RadNet to your portfolios can decrease your overall portfolio volatility.